The Recall Desk
Agency classClass IIOur severity:Severity pendingFDA (Drugs)·D-0165-2027·Announced 2026-11-11

CIPROFLOXACIN (CIPROFLOXACIN)

CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

The agency’s classification

FDA (Drugs): Class II

Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work

Severity not yet assessed

We have not scored this recall against our rubric yet, so we are not showing a severity rating or our usual guidance. The agency’s own notice below is the authoritative source — read it first.

Plain-English summary

CGMP Deviations: N-nitroso-ciprofloxacin results above the FDA recommended interim control limit.

The recalled product

Product
CIPROFLOXACIN (CIPROFLOXACIN)
Brand
CIPROFLOXACIN
Affected units
29,085

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (4)

  • Lot# CB496A
  • Exp. 12/31/2026 Lot# CB497A
  • Exp. 12/31/2026 Lot# CB498A
  • Exp. 12/31/2026

Distribution

Distributed nationwide across the United States.